Wells Fargo notes that Summit Therapeutics (SMMT) partner Akeso (AKESF) received approval from China’s NMPA for ivonescimab as a monotherapy ...

The frequency of high blood glucose among patients receiving PI3K/Akt inhibitors to treat breast cancer has some oncologists ...

A novel combination therapy offers better outcomes for patients with KRAS G12C metastatic colorectal cancer that have stopped ...

New research uncovers key factors driving survival and treatment response in patients with HER2-positive breast cancer ...

Prior screening mammography linked to earlier stage at breast cancer diagnosis, lower breast cancer mortality.

CURE provides access to the cancer news, latest oncology research & expert insights that serve as a guide to every stage of ...

Enhertu (fam-trastuzumab deruxtecan-nxki) is currently indicated as a second-line therapy for HER2-positive metastatic breast cancer.

The trial aims to assess the safety and efficacy of Enhertu, either as a single agent or with pertuzumab, against the THP.

A recent review published in Genes & Diseases sheds light on the complex and multifaceted role of RNA-binding proteins (RBPs) in cancer progression, ...

Bicara Therapeutics shows potential to reshape cancer care with ficerafusp alfa and robust funding post-IPO. Find out why ...